HIGHFDA DEVICE

Meridian Bioscience Recalls Revogene C. difficile Assay Over False-Negative Risk

Meridian Bioscience recalled 211 units of the Revogene C. difficile diagnostic assay on December 5, 2025. Users may experience false-negative results due to a decline in performance over time. Patients and healthcare providers must stop using the device immediately.

Official notice
Meridian BioscienceHealth & Personal CareMedical DevicesUDI-DI: 00840733102349Lot Numbers: 410300U195410300U196

Source-backed recall notice

No product image was available from the source feed.

Official source
FDA DEVICE
Recall date
December 5, 2025
Status
ACTIVE
Severity
8/10

Quick Facts at a Glance

Recall Date
December 5, 2025
Hazard Level
HIGH
Brand
Meridian Bioscience
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL

What to Do Now

Use this page like a recall checklist: verify the product first, then act on the official remedy.

Immediate steps

  1. 1Stop using the product until you confirm whether it is included in the recall.
  2. 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
  3. 3Follow the official remedy from FDA - Medical Devices; save photos, receipts, labels, and correspondence before contacting the company.
  4. 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.

Check these identifiers

Brand
Meridian Bioscience
Product type
Diagnostic Assay
Model numbers
UDI-DI: 00840733102349, Lot Numbers: 410300U195, 410300U196, 410300U197, 410300U201
Sold at
Multiple Retailers
Where affected
ALL

Recall Timeline

Key dates and source checks for this recall record.

  1. Recall announced

    December 5, 2025

  2. Reported by FDA DEVICE

    January 14, 2026

  3. RecallRadar source check

    January 21, 2026

  4. Consumer action

    Use the official remedy and keep documentation.

Hazard Information

The affected lots show a decline in performance over time, which may lead to false-negative results.

What You Should Do

Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Meridian Bioscience Inc or your healthcare provider for instructions. Notification method: Letter

About This Product

The Revogene C. difficile assay is used to diagnose C. difficile infections, which can lead to severe gastrointestinal issues. Healthcare providers rely on accurate test results for effective treatment.

Why This Is Dangerous

The decline in performance over time may prevent the assay from detecting the presence of C. difficile, resulting in false-negative results. This could lead to misdiagnosis and lack of essential treatment for patients.

Industry Context

This recall is not part of a broader industry pattern.

Real-World Impact

Consumers may face health risks due to potential misdiagnosis. Delayed treatment for C. difficile infections can lead to serious health complications.

Practical Guidance

How to identify if yours is affected

  1. Locate the catalog number 410300 on the product packaging.
  2. If your product matches these details, it is affected by the recall.

Where to find product info

The catalog and lot numbers are typically found on the product packaging or on the label attached to the assay.

What timeline to expect

Expect a refund processing timeline of approximately 4-6 weeks after returning the product.

If the manufacturer is unresponsive

  • Document your communications with the company.
  • Reach out again via phone or email.
  • Consider filing a complaint with the FDA if no response is received.

How to prevent similar issues

  • When purchasing medical devices, verify the manufacturer's reputation and recall history.
  • Always check for recent recalls before using diagnostic devices.
  • Consult healthcare professionals for alternative testing options if necessary.

Documentation advice

Keep records of your product details, receipts, and any correspondence with the manufacturer regarding the recall.

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

The recalled product is the Revogene C. difficile in vitro diagnostic assay with Catalog Number 410300. It was distributed nationwide in the US and in Italy. The affected lot numbers are 410300U195, 410300U196, 410300U197, and 410300U201.

Key Facts

  • False-negative risk due to performance decline
  • Nationwide distribution in the US and Italy
  • Stop using the device immediately

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERAL
Injury Types
OTHER

Product Classification

Product Details

Model Numbers
UDI-DI: 00840733102349
Lot Numbers: 410300U195
410300U196
410300U197
410300U201
Affected States
ALL
Report Date
January 14, 2026
Recall Status
ACTIVE

Related Recalls

Health & Personal Care
MEDIUM

Taro Pharmaceuticals Withdraws Diclofenac Sodium Gel Over Viscosity Issues

Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.

BEEKEEPER'S NATURALS USA
Microbial Contamination
Read more
Health & Personal Care
MEDIUM

AvKARE Recalls Rosuvastatin Tablets Due to Dissolution Issues

AvKARE recalled 7,991 cartons of Rosuvastatin Tablets on December 31, 2025. The recall stems from the product being out of specification for dissolution. Consumers should stop using the medication immediately and consult healthcare providers for guidance.

SUN PHARMACEUTICAL INDUSTRIES
Labeling: Not
Read more